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ABSTRACT: Self-powered drug delivery systems based on conductive polymers (CPs) that eliminate the need for external power 
sources, are of significant interest for use in clinical applications. Osmium redox polymer mediated glucose/O2 enzymatic biofuel 
cells (EBFCs) were prepared with an additional CP-drug layer on the cathode. On discharging the EBFCs in the presence of glucose 
and dioxygen, model drug compounds incorporated in the CP layer were rapidly released with negligible amounts released when 
the EBFCs were held at open circuit. Controlled and ex situ release of three model compounds, ibuprofen (IBU), fluorescein (FLU) 
and 4',6-diamidino-2-phenylindole (DAPI), was achieved with this self-powered drug release system. DAPI released in situ in cell 
culture media was incorporated into retinal pigment epithelium (RPE) cells. This work demonstrates a proof-of-concept responsive 
drug release system that may be used in implantable devices. 
INTRODUCTION 1 
Enzymatic biofuel cells (EBFCs) consisting of sugar-oxidising 2 
bioanodes and oxygen-reduction biocathodes can harvest 3 
electricity from chemical energy.1-3 When consuming a fuel, 4 
such as glucose, that is present in physiological fluids4, 5 
membrane-less EBFCs possess significant potential for use as 6 
activators for implantable medical devices. A significant 7 
advantage of EBFCs lies in the continuous supply of fuel, as 8 
opposed to batteries, which need replacement.5-7 Significant 9 
challenges such as operational stability together with 10 
mismatches between the output voltages of EBFCs (typically 11 
below 1 V) and the minimum activation input voltage required 12 
to operate many microelectronic devices (generally in the 13 
range 1-3 V with recent reports describing lower voltages of 0.5 14 
V8) hinder the application of EBFCs  as direct and independent 15 
power sources6.  16 
A possible solution is to develop self-powered devices9 that 17 
utilise EBFCs directly to enable functions such as biosensing10-18 
11 and self-sustained pulse generators.12-13 Responsive polymer 19 
based drug delivery systems have gained significant attention 20 
in recent years.14-16 Self-powered release systems have been 21 
described, with the potential to act as “ sense-act-treat ”22 
devices.17-20 Such systems generally use abiotic cathodes such 23 
as a Fe3+-cross-linked alginate polymer loaded with drug 24 
molecules. Reduction of Fe3+ to Fe2+, by a coupled bioanode in 25 
the presence of sugars results in dissolution of the polymer 26 
releasing the entrapped species.18-19 However, alginate 27 
polymers are unstable at high pH and the release of Fe2+ (or 28 
other metal ions) may not be desirable. Nishizawa et al. 29 
developed an iontophoresis patch that utilised an EBFC for the 30 
transdermal delivery of ascorbyl glucoside and rhodamine B.21 31 
Such an approach is restricted to transdermal applications and 32 
is not suitable for implantable applications.  33 
On account of their high electrical conductivity, mechanical 34 
stability and ease of preparation, conducting polymers (CP) are 35 
used in a range of applications that include light emitting 36 
diodes, capacitors, electrochromic devices, actuators, etc.22-23 37 
The preparation of the polymers entails oxidation of a 38 
monomer species, followed by a chain reaction to form the CP. 39 
Due to the charged nature of the CP, counterions are 40 
incorporated into the polymer to balance the charge on the 41 
polymer.23-24 On reduction of the polymer, these dopant ions 42 
are subsequently expelled. Typically, the dopants are anionic 43 
or cationic components of the electrolyte. Other charged 44 
species present in the electrolyte solution can also be 45 
incorporated as dopants in the polymer and then released on 46 
reduction of the polymer. Galvanic cell based self-powered 47 
drug delivery systems25 consisting of a conductive polymer 48 
(CP) cathode, with the drug incorporated within the polymer 49 
matrix, and a metal (e.g. Mg and Zn) anode with a very negative 50 
half-cell potential have been described.26 Reduction of the CP 51 
film by the metal anode leads to the expulsion of the 52 
incorporated drug. Such devices can suffer the disadvantage of 53 
release of metal ions as described above and the inability to 54 
pause oxidation of the metal anode,26 diminishing the capacity 55 
to regulate the rate of release. 56 
In this report, we describe a versatile strategy to prepare a 57 
self-powered drug release system based on EBFCs which has 58 
the potential to be used in vivo. A membrane-less glucose/O2 59 
EBFC, that can generate electricity from glucose and dioxygen, 60 
was prepared using a [Os(2,2′-61 
bipyridine)2(polyvinylimidazole)10Cl]+/2+ (Os(bpy)2PVI) 62 
mediated glucose oxidase (GOx) anode and a Os(bpy)2PVI 63 
mediated bilirubin oxidase (BOx) cathode (Scheme S1).12 Thin 64 
nanoporous gold (NPG, pore size: ca. 30 nm, roughness factor: 65 
7-8) films with a thickness of ca. 100 nm were used as 66 
biocompatible and conductive electrodes.12, 27-29 CP layers were 67 
electropolymerized onto the NPG/Os(bpy)2PVI-BOx cathodes 68 
in the presence of model drugs. Controlled release of the drugs 69 
was switched “on” in the presence of glucose and dioxygen and 70 
switched “off” at open circuit. This proposed approach is 71 
unique and avoids the limitations outlined above with self-72 
powered electrically triggered drug release systems (see 73 
summary in Table S1). No external electrical input is required 74 
for the controlled drug release process described here. Two 75 
anionic (ibuprofen (IBU) and fluorescein (FLU)), and a cationic 76 
species (4',6-diamidino-2-phenylindole (DAPI)) were 77 
examined (Scheme S2). IBU is one of the most-widely 78 
employed non-steroidal anti-inflammatory drug and was 79 
selected as a model drug to demonstrate the feasibility of the 80 
approach. FLU and DAPI were selected as model fluorescent 81 
compounds and DAPI in particular with due to its ability to 82 
stain cell nuclei. Controlled release of the three model 83 
compounds, was successfully demonstrated, illustrating the 84 
general nature of the approach. 85 
 86 
RESULTS AND DISCUSSION 87 
Controlled Release of Anionic Drug Ibuprofen (IBU). IBU 88 
can be doped into poly(3,4-ethylenedioxythiophene) (PEDOT) 89 
as negatively charged doping ions.30 Previous work30 has 90 
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shown that IBU can be released in a controlled manner by 91 
applying a negative potential to reduce PEDOT which 92 
undergoes a de-doping process (Eq. S1). Electrically triggered 93 
drug release is simple and versatile as it enables the on-94 
demand release of drugs with the concomitant requirement for 95 
intermittent dosage of medications as needed. However, in situ 96 
applications are limited when external power input is needed. 97 
In the proposed approach, a PEDOT-IBU layer was 98 
electrodeposited onto a NPG/Os(bpy)2PVI-BOx biocathode 99 
(Fig. 1A, Fig. S1). The reduction of dioxygen at the cathode 100 
occurred with concomitant reduction of the outer PEDOT layer 101 
releasing IBU into solution. A similar methodology was applied 102 
for the self-powered release of the commonly used 103 
fluorophores FLU (Fig. 2A) and DAPI (Fig. 3A). 104 
Fig. 1B shows the biocatalytic dioxygen-reduction response 105 
of the NPG/Os(bpy)2PVI-BOx/PEDOT-IBU biocathode. The 106 
electrode exhibited a pair of redox peaks in N2 bubbled PBS, 107 
with a midpoint potential (Em) of 0.191 V vs. SCE, assigned to 108 
the redox behavior of the Os2+/3+ couple. The faradaic response 109 
of Os2+/3+ was superimposed on the pseudo-capacitive current 110 
of PEDOT (Fig. S2). On comparison of the cyclic 111 
voltammograms (CVs) of NPG/Os(bpy)2PVI-BOx/PEDOT-IBU 112 
and NPG/Os(bpy)2PVI-BOx (Fig. S2) the capacitance of the 113 
latter increased from 415 to 570 μC cm-2, indicative of the 114 
formation of an additional PEDOT-IBU layer. In an air-115 
equilibrated solution, electrocatalytic reduction of oxygen 116 
commenced at 0.327 V vs. SCE, reaching a maximum net 117 
catalytic current density (jnet) of 15.8±0.4 μA cm-2 at 0.121 V, a 118 
value lower than that of the NPG/Os(bpy)2PVI-BOx electrode 119 
(31.5±2.3 μA cm-2 at 0.178 V) (Fig. S2). The presence of IBU 120 
showed no inhibitory effects on the activities of GOx and BOx 121 
(Fig. S3). Enzymatic assay of immobilized BOx after coating 122 
with the second PEDOT-IBU layer showed a somewhat lower 123 
activity (details in Experimental Section). As observed with the 124 
electrochemical response, this decrease can be ascribed to O2 125 
diffusional limitations arising from the additional polymeric 126 
layer. Scanning electron microscopic (SEM) (Fig. S4), 127 
transmission electron microscopic (TEM) (Fig. S5) and atomic 128 
force microscopic (AFM) (Fig. S6) images of the bare and 129 
modified electrodes  indicate that there was a buildup of 130 
polymer layers on the electrode surface. Although it was not 131 
possible to distinguish between the two layers using TEM, the 132 
thickness of the coating layer on Os(bpy)2PVI-BOx/PEDOT-IBU 133 
(6.7±1.4 nm) was larger than that of Os(bpy)2PVI-BOx (3.7±0.4 134 
nm) (Fig. S5). Using Fourier transform infrared spectroscopy 135 
(FTIR) (Fig. S7), the first coating layer of Os(bpy)2PVI-BOx 136 
showed bands at 1455 cm-1 (C=C stretching) and 1418 cm-1 137 
(imidazole cycle stretching) corresponding to the presence of 138 
polyvinylimidazole. The appearance of a band at 1385 cm-1 139 
band that was not present with the Os(bpy)2PVI-BOx modified 140 
electrode can be assigned to C=C stretching in the thiophene 141 
ring confirmed the successful generation of the second PEDOT-142 
IBU layer. 143 
 The lower jnet was attributed to the reduced rate of mass 144 
transport of O2 to BOx due to steric hindrance by the PEDOT 145 
layer. The decrease in the flux was verified by a control 146 
experiment using a PEDOT layer, without IBU doping on 147 
NPG/Os(bpy)2PVI-BOx, where a significant decrease (72%) in 148 
the catalytic response was also observed at 0 V vs. SCE (Fig. 149 
S3B). This is consistent with previous reports where NPG 150 
electrodes modified with additional layers displayed lower 151 
responses.12, 31 CVs of NPG/Os(bpy)2PVI-GOx displayed (Fig. 152 
1C) a pair of redox peaks with an Em of +0.188 V vs. SCE in a 153 
blank solution with no substrate, and a jnet of 97.5±9.1 μA cm-2 154 
at +0.201 V vs. SCE and an onset potential of -0.055 V vs. SCE in 155 
the presence of 10 mM glucose. In an air-equilibrated solution 156 
containing 10 mM glucose, the assembled EBFC(1) registered 157 
an open-circuit voltage (OCV) of 0.377 V and a maximum power 158 
density (Pmax) of 1.35 μW cm-2 at 0.124 V (Fig. 1D). The 159 
obtained OCV was in agreement with the difference between 160 
the onset potentials of the bioanode and the biocathode. The 161 
potential difference between two electrodes modified with the 162 
same Os polymer is based on the Nernstian potential difference 163 
arising from differing ratios of oxidised and reduced Os 164 
polymer at the two electrodes.32 Due to the mediated 165 
biocatalytic reactions (glucose oxidation and oxygen 166 
reduction) at the bioanode and biocathode, the ratio of oxidised 167 
and reduced Os polymer on each electrode will be different, 168 
establishing a potential difference between the two electrodes, 169 
i.e. OCV of an EBFC. The use of the same mediator for EBFCs has 170 
been described in a number of studies.12, 33-34 If required the 171 
OCV can be altered and improved by using two different redox 172 
polymers with redox potentials close to those of the enzymes. 173 
The power density of EBFC(1) is limited by the biocathode 174 
when the glucose concentration is over 3 mM, based on the fact 175 
that the catalytic current density of the bioanode (Fig. S8) is 176 
much higher than that of the biocathode (Fig. 1B). Considering 177 
the glucose concentration in plasma is typically 5 mM or higher, 178 
the power density of the EBFC is thus always limited by the 179 
biocathode. Thus, changing glucose concentrations (when 180 
above 3 mM) would not affect the drug release kinetics. 181 
EBFC(1) registered a half-lifetime of 9.2 h under continuous 182 
operation at 0.15 V in buffer (Fig. S9). 183 
EBFC(1) was discharged at a range of potentials (Fig. 1E) and 184 
the cumulative amount of IBU released was determined from 185 
the absorbance at 222 nm (Fig. S10). The optimal voltage for 186 
release of IBU was 0.15 V, similar to the voltage observed at 187 
Pmax (0.124 V) (Fig. 1D). The relationship between EBFC 188 
voltage and the voltages of the biocathode and bioanode is 189 
given by: Ecell= Ebiocathode -Ebioanode. For Ecell potentials of 0.05, 190 
0.15 and 0.3 V of EBFC(1), we examined the corresponding 191 
voltages for the biocathode (0.066, 0.12 and 0.25 V vs. SCE) and 192 
bioanode (0.016, -0.032 and -0.05 V vs. SCE), respectively 193 
(Table S2). The amount of IBU released from 194 
NPG/Os(bpy)2PVI-BOx/PEDOT-IBU biocathode solely in a 195 
three-electrode setup was monitored at 0.066, 0.12 and 0.25 V 196 
vs. SCE for 5 min, respectively. When the biocathode was 197 
operating at 0.12 V vs. SCE (Fig. S11), corresponding to 198 
conditions where the voltage of EBFC(1) was 0.15 V, the 199 
amount of IBU released was at a maximum. This is consistent 200 
with the data in Fig. 1B, where the biocathode registered a 201 
maximum current density at 0.12 V vs. SCE. This demonstrates 202 
that the results obtained with the biocathode in a three-203 
electrode cell were consistent with those observed when 204 
operating EBFC(1) in a two-electrode cell. We thus can 205 
conclude that the optimal rate of release of IBU is obtained 206 
close to the voltage observed at Pmax, enabling more rapid de-207 
doping of PEDOT-IBU, enhancing the rate of  release of IBU. 208 
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Figure 1. (A) Schematic illustration of controlled IBU release 210 
based on an EBFC(1); Cyclic voltammograms (CVs) of the 211 
NPG/Os(bpy)2PVI-BOx/PEDOT-IBU biocathode (B) and 212 
NPG/Os(bpy)2PVI-GOx bioanode (C) in 0.1 M pH 7.0 phosphate 213 
buffer solution (PBS) at a scan rate of 5 mV s-1; (D) Power and 214 
current density profiles of the EBFC(1) consisting of a 215 
NPG/Os(bpy)2PVI-GOx bioanode and a NPG/Os(bpy)2PVI-216 
BOx/PEDOT-IBU biocathode in air-equilibrated solution 217 
containing 10 mM glucose; (Inset of D) the control cell was 218 
composed of a NPG/Os(bpy)2PVI-GOx bioanode and a 219 
NPG/Os(bpy)2PVI/PEDOT-IBU cathode; (E) Cumulative 220 
amount of IBU released from the IBU loaded EBFC(1) operating 221 
at various voltages for 10 min; (F) Cumulative amount of IBU 222 
released by EBFC(1) operating at 0.15 V (red line) and at open-223 
circuit mode (spontaneous release) (black line); (G) 224 
Cumulative amount of IBU released by  EBFC(1) operating in 225 
“on-off” mode: with “on” representing a potential of 0.15 V and 226 
“off” the open-circuit mode.  227 
 228 
The time profiles of release of IBU from the self-powered 229 
system at 0.15 V and at open-circuit are shown in Fig. 1F. The 230 
amount of drug loaded on the electrode was estimated to be 231 
570±32 µg cm-2. Rapid IBU release occurred during the initial 232 
period of discharge (10 min), reaching an equilibrium value of 233 
197±20 μg cm-2 in ca. 30 min, corresponding to 35% release of 234 
the total load of IBU. This time frame is similar to that 235 
previously reported using a Pt electrode with a PEDOT/IBU 236 
layer where IBU was released on reduction of PEDOT with the 237 
maximum rate of release occurring at a potential of -0.5 V vs. 238 
Ag/AgCl.30 In that system, release of IBU required the 239 
application of a potential bias from an external source. 240 
Os(byp)2PVI-BOx has a midpoint potential of 0.191 V vs. SCE, 241 
while PEDOT can be reduced at a similar potential12, 35, 242 
indicating that both Os(byp)2PVI and PEDOT-IBU can be 243 
reduced by accepting electrons from the bioanode via the 244 
external circuit. The reduction of the PEDOT-IBU layer was 245 
confirmed by an increase in absorbance at 500 nm after 246 
operation of the EBFC36 (Fig. S12). Although the detailed 247 
mechanism of operation has to be established, electron 248 
transfer (ET) between the underlying Os(byp)2PVI and PEDOT-249 
IBU layers was evident by (i) the successful 250 
electropolymerization of EDOT onto the Os(bpy)2PVI layer 251 
(Fig. S1) and (ii) CVs of NPG/Os(bpy)2PVI-BOx/PEDOT-IBU 252 
electrodes that showed faradaic peaks corresponding to the 253 
redox reaction of Os2+/3+ superimposed on the 254 
charge/discharge capacitive currents of PEDOT (Fig. S2). 255 
The amount of spontaneous release of IBU from 256 
NPG/Os(bpy)2PVI-BOx/PEDOT-IBU was not significant (12% 257 
of the amount at a potential of 0.15 V) (Fig. 1F) and can be 258 
attributed to the release of loosely-bound and physically-259 
absorbed species. The use of longer washing/soaking times 260 
would clearly reduce this effect. This low level of spontaneous 261 
release provides evidence that release by EBFC(1) at 0.15 V 262 
was occurring in a controlled manner. An “on-off” operating 263 
sequence for EBFC(1) working alternatively at 0.15 V (2 min) 264 
and open-circuit (2 min) confirmed the controlled release of 265 
IBU, with an immediate decrease in the amount of IBU released 266 
during the “off” stages (Fig. 1G). As a control, a cell using the 267 
same anode, but with a NPG/Os(bpy)2PVI/PEDOT-IBU cathode 268 
without BOx (Fig. 1D), had an OCV of 0.109 V and a negligible 269 
Pmax of 0.01 μW cm-2, highlighting the requirement for BOx at 270 
the cathode. This data demonstrates that in the presence of BOx 271 
and the accompanying oxygen reduction reaction, a potential 272 
difference (i.e. OCV) is established between the cathode and the 273 
NPG/Os(bpy)2PVI-GOx bioanode that enables release of IBU. 274 
The control cell without BOx cannot be used for self-powered 275 
drug release as it does not provide a sufficient nor a sustained 276 
power output, exhibiting decreased power and voltage on 277 
consecutive testing (Fig. S13). This cell when operated at 0.07 278 
V showed negligible levels of release of IBU in comparison to 279 
spontaneous release. Further control experiments were 280 
performed by coating PEDOT-IBU onto the NPG/Os(bpy)2PVI-281 
GOx anode instead of the cathode (Fig. S14). The assembled 282 
EBFC showed negligible levels of release of IBU at 0.15 V. These 283 
results demonstrate that reduction of the PEDOT-IBU layer 284 
(the presence of BOx) is necessary to enable release of IBU.20 285 
 286 
Controlled Release of Anionic Fluorescein (FLU) Dye. The 287 
release of FLU, which has been widely used as a model guest 288 
molecule,37-39 was evaluated. Polypyrrole (PPy)40 has been 289 
reported to be more effective than PEDOT for the release of 290 
dyes such as FLU, although the basis for this is unclear.26 291 
Accordingly, a PPy-FLU layer was electrodeposited onto a 292 
NPG/Os(bpy)2PVI-BOx cathode (Fig. 2A) and the release of 293 
FLU was monitored by fluorescence (Fig. S15). The 294 
NPG/Os(bpy)2PVI-BOx/PPy-FLU biocathode showed a 295 
reasonable biocatalytic response towards the reduction of 296 
dioxygen, with a jnet of 15.3±0.4 μA cm-2 at +0.135 V vs. SCE and 297 
an onset potential of 0.311 V vs. SCE (Fig. 2B). The presence of 298 
FLU in solution posed no inhibitory effects on the performance 299 
of the bioelectrodes (Fig. S16). When coupled with a 300 
NPG/Os(bpy)2PVI-GOx bioanode, the resulting EBFC(2) 301 
possessed a Pmax of 1.14 μW cm-2 at 0.146 V and an OCV of 0.39 302 
V (Fig. 2C), results comparable to those observed with 303 
EBFC(1).  304 
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Figure 2. (A) Scheme of the controlled FLU release system; 306 
CVs of the NPG/Os(bpy)2PVI-BOx/PPy-FLU biocathode (B) in 307 
0.1 M pH 7.0 PBS at 5 mV s-1; (C) Power and current density 308 
profiles of EBFC(2) consisting of a NPG/Os(bpy)2PVI-GOx 309 
bioanode and a NPG/Os(bpy)2PVI-BOx/PPy-FLU biocathode in 310 
air-equilibrated solution containing 10 mM glucose; (D) 311 
Cumulative amount of IBU released during the operation of 312 
EBFC(2) at various potentials; (E) Cumulative amount of FLU 313 
released during the EBFC(2) operating in “on-off” mode: “on” 314 
indicates that  EBFC(2) was operating at 0.15 V; “off” indicates 315 
operating at open-circuit mode (blue line). 316 
 317 
The FLU doped PPy layer was reduced at the cathode due to 318 
the dioxygen-reduction reaction, enabling the release of FLU 319 
(Eq. S2, Fig. 2A). The cumulative amount of FLU released was 320 
recorded at a range of potentials (Fig. 2D).  Rapid release of 321 
FLU occurred in the first 5 min, when the EBFC was operating 322 
at 0.15 V, with equilibrium levels of release attained in ca. 10 323 
min, in contrast to ca. 30 min for IBU. The equilibrium amount 324 
of FLU released in solution was 101.5±29.3, 36.9±5.3, 21.3±0.3 325 
and 5.6±0.3 ng cm-2 within 25 min for 0.15, 0.05, 0.3 V and for 326 
spontaneous release, respectively. This is in agreement with 327 
the release of IBU (Fig. 1E) where the maximum amount 328 
released was achieved at the same potential as Pmax. The 329 
dramatic difference (18-fold) between the amounts of FLU 330 
released at 0.15 V and in a spontaneous manner confirmed that 331 
an efficient delivery process was feasible with the EBFC based 332 
system. The release profile for FLU that was obtained with 333 
sequential application of “on” and “off” potentials is further 334 
evidence of a controlled release system, as the amount of FLU 335 
released attained a plateau during the intermittent “OFF” steps 336 
(Fig. 2E). 337 
 338 
In situ Release of Cationic Fluorophore DAPI in Cell 339 
Culture Media. Finally, the in situ release of the cationic 340 
fluorophore, DAPI, by an EBFC based system in Dulbecco's 341 
modified Eagle medium (DMEM) cell culture media containing 342 
ca. 17.5 mM glucose was performed (Fig. 3A). DAPI can be used 343 
to stain the nucleus and can be used   as a fluorescent probe of 344 
the cells. The uptake of the dye by retinal pigment epithelium 345 
(RPE) cell lines was investigated using confocal microscopy. In 346 
contrast to anionic species such as IBU and FLU, cationic 347 
materials such as DAPI can be incorporated into PPy via 348 
electrostatic interactions and then released when these 349 
electrostatic interactions are altered during the redox 350 
process.41 Thompson et al. employed p-toluenesulfonate (pTS) 351 
as an anionic dopant of PPy to release neurotrophin 352 
(cationic).42 Release of neurotrophin occurred when the redox 353 
state of PPy was altered, due to changes in electrostatic 354 
interactions between the dopants and PPy.  355 
DAPI was encapsulated into PPy films in the presence of pTS 356 
during electropolymerization of a polypyrrole layer on a 357 
NPG/Os(bpy)2PVI-Box modified electrode. The 358 
NPG/Os(bpy)2PVI-BOx/PPy-pTS-DAPI cathode exhibited a net 359 
catalytic current density of 26.8±1.9 μA cm-2 at 0.17 V vs. SCE 360 
undergoing oxygen reduction in air-equilibrated cell culture 361 
media (Fig. 3B). The onset potential was 0.35 V vs. SCE. 362 
EBFC(3) generated a Pmax of 2.05 μW cm-2 at 0.135 V with an 363 
OCV of 0.387 V in the same medium (Fig. 3C). Ex situ release of 364 
DAPI in PBS at 0.15 V was observed, with an initial fast rate of 365 
release for 20 min, attaining an equilibrium value within 90 366 
min (Fig. S17 and S18). The amount of DAPI released at a 367 
potential of 0.15 V was 102.5±10.5 ng cm-2, 6 times higher than 368 
that observed by spontaneous release (Fig. S18), 369 
demonstrating that controlled delivery could be achieved with 370 
this system. 371 
In situ release of DAPI by the EBFC(3) operating at 0.15 V was 372 
conducted in cell culture media with incubated RPE cells for 30 373 
min. Confocal microscopic images showed blue-fluorescent 374 
RPE cells when excited at 405 nm, indicating the successful 375 
cellular uptake of permeable DAPI (Fig. 3D and 3E). This also 376 
implies that the structure of DAPI was unaffected by the EBFC 377 
based drug release system. Conversely, a negative control with 378 
open-circuit potential release of the EBFC(3) resulted in a very 379 
low density of stained RPE cells (Fig. 3F and 3G). The 380 
morphology of the cells was unchanged in the presence of the 381 
EBFC(3), indicating that the system showed a high degree of 382 
biocompatibility in vitro (Fig. 3D and 3F).  383 
CellTrace™ Yellow, which can be retained by cell membranes, 384 
was used to label all cells in a particular field of view and 385 
imaged by fluorescence microscopy (excited at 543 nm). 386 
Characterisation of the successful staining of cell nuclei was 387 
based on the detection of cell labelling by cell trackers and 388 
identification of nuclear associated fluorescence intensity of 389 
DAPI at 405 nm. Quantitative analysis of five random areas 390 
with more than 100 cells per FOV was performed. Fig. 3H 391 
illustrates the positive labeling to similar levels of cells by cell 392 
trace in both control and loaded conditions. In contrast, nuclear 393 
labelling associated with DAPI fluorescence was significantly 394 
enriched when EBFC(3) was operating at 0.15 V. Similar results 395 
are observed when assessing DAPI staining in isolation. This 396 
was further verified by comparing the overall fluorescence 397 
intensity of DAPI per FOV for the loaded and unloaded control 398 
(18.7±3.0 vs. 3.5±1.5) (Fig. 3I). A t-value of 4.561 (P < 0.01) 399 
with a degree of freedom of 8 was obtained from the unpaired 400 
two tailed student’s t-Test, confirming a statistically significant 401 
difference between the loaded and unloaded control. Thus, in 402 
vitro experiments established the viability and effectiveness of 403 




Figure 3. (A) Scheme of in situ DAPI release in a cell culture medium; (B) CVs of the NPG/Os(bpy)2PVI-BOx/PPy-pTS-DAPI 
biocathode in cell culture media (5 mV s-1); (C) Power and current density profiles of the EBFC(3) consisting of a NPG/Os(bpy)2PVI-
GOx bioanode and a NPG/Os(bpy)2PVI-BOx/PPy-pTS-DAPI biocathode in air-equilibrated cell culture media; (D-G). Confocal 
fluorescence images of RPE cells after incubation in the cell culture media with the EBFC(3) operation at 0.15 V (D, E) and open 
circuit for 30 min (F, G):  (D, F) overlay images of the Blue fluorescence channel and transmission images, (E, G) Blue fluorescence 
images; scale bar: 20 μm. (H) Scatter-plot of the fluorescence intensity of cell-tracker vs. DAPI intensity; Green and grey columns 
correspond to the positive and negative control. (I) The plot of DAPI intensity per FOV. Values were represented as the mean 
(horizontal lines) ± standard error of the mean of five separate experiments (circles).  
 
CONCLUSIONS 
In summary, a self-powered, controlled drug release system, 
based on bi-layer modified electrodes has been demonstrated. 
Three model compounds, bearing negative, neutral or positive 
charges were released in a controlled manner ex situ. The 
maximum amounts released depended on the power density of 
the EBFC. The blue fluorophore DAPI was encapsulated in 
polypyrrole and released from an EBFC system to efficiently 
stain RPE cells, indicating that the system was biocompatible43. 
The approach is of interest for use with other redox enzymes 
and fuels and for feasibility of miniaturisation. The preliminary 
results demonstrate possible applications of the EBFC based 
system for “on demand” implantable drug release system. 
Further evaluation of the suitability of the approach described 
will require examining the stability and response of the cell 
after sterilization and on implantation in tissue. 
 
EXPERIMENTAL SECTION 
Materials. D-(+)-glucose (99.5%), 3,4-
ethylenedioxythiophene (EDOT, 97%), pyrrole (98%), GOx 
from Aspergillus niger (EC 1.1.3.4, type II, ≥15,000 U g-1), 
sodium phosphate (monobasic dehydrate ≥99% and dibasic 
≥99%), ibuprofen sodium salt (IBU, ≥98%), polyethylene glycol 
3400 (PEG3400), fluorescein sodium salt (FLU), sodium p-
toluenesulfonate (pTS, 95%), Dulbecco's modified Eagle's 
medium/nutrient mixture F-12 Ham (DMEM:F12 HAM (1:1 
v/v)), sodium bicarbonate, antibiotic-antimycotic solutions, 
hygromycin, paraformaldehyde (PFA), 2,2’-azinobis (3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt 
(ABTS) and sulfuric acid (H2SO4, 95-98%) were obtained from 
Sigma-Aldrich Ireland, Ltd. CellTrace™ Yellow and 4',6-
diamidino-2-phenylindole (DAPI) were purchased from 
Thermo Fisher Scientific. Myrothecium verrucaria BOx (EC 
1.3.3.5, 2.63 U mg-1) was from Amano Enzyme Inc., Japan. 
Os(bpy)2PVI was synthesised via an established procedure 44-
45. Deionised water (18.2 MΩ cm, Elga Purelab Ultra, UK) was 
used to prepare all the solutions.  
Nanoporous gold (NPG, pore size ca. 30 nm) modified 
electrodes were prepared as described previously.12, 27 100 nm 
thick Au/Ag leaf alloy leaves (12-carat, Eytzinger, Germany) 
were dealloyed in concentrated HNO3 (Sigma-Aldrich) for 
30 min at 30 °C. The resulting NPG films were then attached 
onto pre-polished glassy carbon electrodes (GCEs, diameter: 
4 mm). Cyclic voltammetry (CV) of NPG in 1 M H2SO4 for 15 
cycles were performed to create clean surfaces and left to dry 
naturally. 
Bioelectrode Construction and Drug Loading. 
NPG/Os(bpy)2PVI-GOx and NPG/Os(bpy)2PVI-BOx 
bioelectrodes were prepared separately. A 5.3 μl aliquot of a 6 
mg ml-1 aqueous suspension of Os(bpy)2PVI, was combined 
with 1.3 μl of a 15 mg ml-1 aqueous solution of PEGDGE and3.2 
μl of a 10 mg ml-1 solution of either GOx or BOx. All the 
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components were homogenously mixed by vortexing. The 
surface of the NPG electrode was fully covered by a drop of the 
solution, and immediately placed in a vacuum desiccator 
connected to a vacuum pump for 10 min. The electrodes were 
then placed in a refrigerator and allowed to dry overnight in 
the dark at 4oC.  
To load IBU, a second layer of PEDOT doped with IBU was 
subsequently electrodeposited onto the NPG/Os(bpy)2PVI-
BOx biocathode, resulting in NPG/Os(bpy)2PVI-BOx/PEDOT-
IBU. An electrodeposition solution containing PBS (0.1 M, pH 
7.0), 2 mM polyethylene glycol 3400 (PEG3400), 20 mM EDOT 
and 10 mM IBU was used. Electrodeposition was performed 
using pulse sequence comprised of 0.9 V (2 s) and -0.4 V (3 s) 
for a total time of 300 s. The oxidation potential of 0.9 V was 
based on the cyclic voltammograms for the 
electropolymerization of EDOT (Fig. S1). The electrodes were 
then soaked in PBS for 30 min to remove any loosely attached 
IBU. The IBU loading in the PEDOT-IBU film was estimated by 
the concentration difference of IBU in the 
electropolymerization electrolyte before and after 
electropolymerization. In order to perform spectroscopic 
studies of the PEDOT-IBU layer, the same procedure was 
employed to coat Os(bpy)2PVI-BOx/PEDOT-IBU onto an 
indium tin oxide coated glass (ITO) or gold foil. Enzymatic 
activity of the immobilized BOx was monitored by soaking the 
electrodes in 2 mL of air-equilibrated 50 M ABTS for 5 min, 
and the absorbance at 420 nm monitored. The absorbance 
reached 0.462±0.153 and 0.318±0.008 for NPG/Os(bpy)2PVI-
BOx and NPG/Os(bpy)2PVI-BOx/PEDOT-IBU, respectively.  
To load FLU, a second layer of PPy doped with FLU was 
electrodeposited onto NPG/Os(bpy)2PVI-BOx, resulting in 
NPG/Os(bpy)2PVI-BOx/PPy-FLU. An electrodeposition 
solution containing 0.1 M pH 7.0 PBS with 20 mM PPy and 50 
µM FLU was prepared. A 60 s pulse sequence (0.9 V (2 s) and -
0.4 V (3 s)) was applied. The electrodes were then gently rinsed 
with PBS for 30 min.  
For the biocathode, a second layer of PPy doped with pTS and 
DAPI was electrodeposited onto NPG/Os(bpy)2PVI-BOx, 
leading to NPG/Os(bpy)2PVI-BOx/PPy-pTS-DAPI. The 
electrodeposition solution contained 0.1 M pH 7.0 PBS with 25 
mM PPy, 0.1 M pTS and 200 µM DAPI. A 60 s pulse sequence 
comprising 0.9 V (2 s) and -0.4 V (3 s) was used. Physically 
adsorbed DAPI was removed by immersing the electrodes in 
PBS for 30 min. 
Morphology and Composition Characterisation. Scanning 
electron microscopy (SEM, Hitachi SU-70, 20 kV) and 
transmission electron microscopy (TEM, Tecnai G2 T20, 200 
kV) were used to characterise the electrode surface. The 
thicknesses of the modification layers were estimated using 
TEM, using the contrast difference between the gold skeleton 
and the coating layers. The average pore size of NPG and 
deposition layer thickness were obtained by measuring at least 
30 times with ImageJ software (National Institutes of Health, 
Bethesda, Maryland) 46. Fourier transform infrared 
spectroscopy (FTIR) measurements of the composite layers 
were performed using a Bruker Optics Alpha‐P spectrometer. 
Gold foils (thickness: 0.1 mm, purity: 99.9%) were used as the 
substrate for polymer modification. ITO coated glass slides 
were used to support NPG for atomic force microscopic (AFM) 
characterisation using a 5500 SPM system (Keysight 
Technologies, Santa Rosa CA, USA) in tapping mode. 
 
1.4. Electrochemical Measurements 
Electrochemical characterisation was carried out using a 
CHI802 potentiostat (CH Instruments, Austin, Texas) with a 
three-electrode system composed of NPG based working 
electrodes, a saturated calomel electrode (SCE) as the 
reference electrode and a platinum counter electrode. Cyclic 
voltammetry was employed to characterise the modified 
electrodes  and the electrochemical capacitance of the 
electrode was calculated from the current densities at 0.4 V vs. 
SCE when there was no faradaic process involved. The net 
catalytic currents were determined by subtracting the 
background currents obtained from the blank CVs from the 
electrocatalytic currents. 
The assembled enzymatic biofuel cells (EBFCs) were analysed 
in a two-electrode system by using a NPG/Os(bpy)2PVI-GOx 
bioanode as the working electrode and various 
NPG/Os(bpy)2PVI-BOx based modified biocathodes as the 
combined counter/reference electrode. To distinguish 
between the EBFCs, EBFC(1), EBFC(2) and EBFC(3) denote 
EBFC comprised of NPG/Os(bpy)2PVI-BOx/PEDOT-IBU, 
NPG/Os(bpy)2PVI-BOx/PPy-FLU and NPG/Os(bpy)2PVI-
BOx/PPy-pTS-DAPI, respectively. The current in the potential 
range between the open circuit voltage (OCV) of the EBFC and 
0 V at 1 mV s-1 was recorded, and subsequently used to 
generate a power density profile. During recording of the 
polarisation curve of the assembled EBFC, the potential of the 
biocathode (Ebiocathode in V vs. SCE) was monitored 
independently using an additional potentiostat (PalmSens 3, 
The Netherlands) by connecting the working electrode and 
counter electrode to the biocathode and a SCE reference 
electrode, respectively. The potential of the bioanode (Ebioanode 
in V vs. SCE) is determined by the voltage difference between 
the potential of the biocathode and the corresponding cell 
voltage of the EBFC (Ecell in V), i.e. Ecell= Ebiocathode -Ebioanode. 
Drug Release Studies. The release of IBU, FLU and DAPI from 
the electrodes was carried out under open circuit mode 
(spontaneous release) or EBFC-triggered mode in 1 mL air-
equilibrated 0.1 M pH 7.0 PBS containing 10 mM glucose, 
respectively. The release of IBU from NPG/Os(bpy)2PVI-
BOx/PEDOT-IBU at different voltages was carried out with a 
three-electrode system in 1 mL air-equilibrated 0.1 M pH 7.0 
PBS. The cumulative release of IBU in solution was monitored 
at 222 nm using a Cary 60 UV-Vis spectrophotometer (Agilent, 
USA). A calibration curve by plotting standard IBU 
concentration versus absorbance at 222 nm was obtained. 
Cumulative release of FLU was monitored using an Agilent Cary 
Eclipse fluorescence spectrophotometer (Germany) with 
excitation at 460 nm. A calibration curve was obtained from the 
emission intensity at 515 nm. The concentration of DAPI 
released in the solution was also measured by the fluorescence 
spectrophotometer with excitation at 340 nm, collecting 
emission intensity at 488 nm. Based on these calibration 
curves, the normalised amounts (nmol cm-2 or μmol cm-2) of 
IBU, FLU and DAPI released were determined. 
In situ Release of DAPI. RPE1 cells (ATCC CRL-4000) were 
maintained at 37°C, 5% CO2, in complete medium (DMEM:F12 
HAM (1:1 v/v) supplemented with 10% fetal bovine serum 
(FBS, ThermoFisher), 0.5% (w/v) sodium bicarbonate, 2 mM 
GlutaMAX (Life Technologies), antibiotic-antimycotic, and 20 
μg mL-1 hygromycin). To perform the assay, cells were seeded 
in 6 well culture dishes at a seeding density of 1 x 106 cells/mL 
and maintained for 48 h prior to experimentation. An EBFC 
consisting of a NPG/Os(bpy)2PVI-GOx bioanode and a 
NPG/Os(bpy)2PVI-BOx/PPy-DAPI biocathode was incubated in 
a 1 mL culturing medium and operated at 0.15 V for 0.5 h. 1 µM 
CellTrace™ Yellow was used to label the cells for 15 min. The 
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stained cells were then washed in PBS followed by fixation with 
4% PFA in PBS for 15 min at room temperature. Fluorescently 
labelled images were acquired by confocal microscopic (Zeiss 
LSM 710; Carl Zeiss). 
Image and Statistical Analysis. Images acquired were 
analyzed by an analysis pipeline created in the CellProfiler 
image analysis software. RPE1 cells were denoted by 
CellTrace™ Yellow and DAPI labelling. Each image-set 
corresponded to 5 fields of view (FOV) with over 100 cells per 
FOV.  
In brief, effects of variation of illumination were corrected 
using an illumination correction function for each channel 
using a median filter (50 x 50 pixels). Each image was 
processed by firstly segmenting the cell boundaries by 
CellTrace™ Yellow labelling using an arbitrary fluorescence 
intensity corresponding to the red fluorescent channel. Next, 
nuclear labelling within this segmented image was identified 
using DAPI labelling corresponding to an arbitrary 
fluorescence intensity, median size (20 to 60 pixels) and shape 
(circular). Identified cells objects were then measured by their 
mean fluorescence intensity in both DAPI and cell tracker 
channels associated with the identified segmented cell regions. 
Data was either expressed as a median per image or and an 
amalgamation of all images. 
GraphPad Prism 5 software was used to undertake the 
statistical analysis (GraphPad Software Inc., La Jolla, CA). For 
comparison of two groups, an unpaired two tailed student’s t-
Test was undertaken and instances of P < 0.05 were 
statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001). All 
values are reported as the mean ± standard error of the mean. 
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